ABSTRACT Background: A low circulating vitamin B-6 concentration, which is an independent risk factor for cardiovascular disease, is commonly seen in human inflammation. Objective: We investigated whether cyclooxygenase inhibitors alter vitamin B-6 metabolism. Design: To investigate whether subjects taking a cyclooxygenase inhibitor had an altered vitamin B-6 profile, we conducted a crosssectional study that involved 150 rheumatoid arthritis patients, with and without cyclooxygenase inhibitor treatments. C57BL/6J mice and hyperlipidemic Syrian hamsters received drug regimens that reflected clinical nonsteroidal antiinflammatory drug (NSAID) uses in treating human inflammation. The impact of long-term physiologic use of selective and nonselective cyclooxygenase inhibitors on vitamin B-6 metabolism was systematically investigated in these independent in vivo models. Results: Patients who were taking cyclooxygenase inhibitors had lower circulating pyridoxal-5#-phosphate, especially those taking NSAIDs .6 mo. Long-term celecoxib and naproxen use reduced hepatic pyridoxal-5#-phosphate in mice. Nonselective cyclooxygenase inhibitor naproxen significantly decreased vitamin B-6 vitamers in the kidney. Conclusions: To our knowledge, we show novel findings that longterm physiologic doses of cyclooxygenase inhibitor may impede the synthesis of the coenzymatically active form of vitamin B-6. Because the cause of vitamin B-6 depletion in inflammation remains unknown, this study provides a potential mechanism that could account for the poor vitamin B-6 status in human inflammation. Moreover, this study further raises concerns about the long-term clinical use of antiinflammatory NSAIDs in humans. Vitamin B-6 status should be carefully monitored in long-term NSAID users. Future randomized placebo-controlled studies are needed to determine the impacts of antiinflammatory cyclooxygenase inhibitor use on vitamin B-6 metabolism in humans. This trial was registered at clinicaltrials.gov as NCT00944866.
INTRODUCTION
The rate-limiting step in arachidonate metabolism is mediated by enzymes known as cyclooxygenases. These enzymes catalyze the biosynthesis of the precursor of prostaglandins, prostacyclin, and thromboxanes. Nonselective nonsteroidal antiinflammatory drugs (NSAIDs) 4 and selective cyclooxygenase-2 inhibitors are widely used for symptom relief in human inflammation. Prolonged NSAID use is not rare in patients who suffer from incurable diseases such as osteoarthritis and rheumatoid arthritis (1) . The popularity and potential benefits of NSAIDs have encouraged more research on NSAIDs. Accumulating evidence has indicated that some NSAIDs can suppress human tumorigenesis in the gastrointestinal tracts (2) . Long-term NSAID use .5 y was reported to be protective against Alzheimer disease (3) .
However, some NSAIDs, including certain selective cyclooxygenase-2 inhibitors, have been related to increased risk of cardiovascular events (4, 5) . In 2004, one of the initial selective cyclooxygenase-2 inhibitors rofecoxib was withdrawn from the market because of excess risk of myocardial infarctions and strokes. Although rofecoxib has a lower gastrointestinal toxicity than naproxen, it was shown to be associated with an unanticipated 5-fold increase in myocardial infarctions compared with naproxen (6), cerebrovascular incident (7), congestive heart failure (8) , stroke (9) , renal syndromes (10, 11) , and arterial hypertension (12) .
The predominant coenzymatically active form of vitamin B-6 pyridoxal-5#-phosphate (PLP) (Figure 1 ) is an essential cofactor for .100 biochemical reactions. Poor vitamin B-6 status leads to numerous adverse consequences because of its crucial role in the human body. Vitamin B-6 deficiency is often present in humans who suffer from rheumatoid arthritis and other inflammatory conditions (13) (14) (15) . In patients with rheumatoid arthritis, the concentration of PLP is associated with multiple markers of inflammation, including disease activity and severity, synovial burden, and pain (14) . In an experimental animal model of arthritis, inflammation caused the tissue-specific depletion of vitamin B-6 (16) . Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation (17) . Abnormal vitamin B-6 status in rheumatoid arthritis has been recognized for decades, but the cause remains to be established (13) (14) (15) 18) . Reduced amounts of vitamin B-6 confer increased risk of atherosclerosis in humans (19) , and vitamin B-6 deficiency induced arteriosclerotic lesions in an animal model (20) . Low plasma PLP concentrations are independently associated with increased risk of coronary artery disease (21) . Combined with the chronic inflammatory condition that has been proved to be atherogenic (22) , a lower plasma PLP concentration (19) in patients with rheumatoid arthritis could further promote cardiovascular diseases in these patients (23) . Patients with rheumatoid arthritis have twice the probability of cardiovascular death compared with that of the general population (24) . Therefore, a well-chosen antiinflammatory therapy for these patients will have implications in many regards.
Conventional NSAIDs and selective cyclooxygenase-2 inhibitors are widely prescribed for patients with inflammation, but data on their effects on vitamin B-6 status are limited. The current study investigated whether the chronic suppression of cyclooxygenase activity through the clinical use of NSAIDs or a cyclooxygenase-2 inhibitor would interfere with vitamin B-6 metabolism. The cross-sectional study provided the association between an altered vitamin B-6 profile and clinical NSAID use in humans. In vivo experimental models enabled us to study how physiologic doses of cyclooxygenase inhibitors may affect vitamin B-6 metabolism in tissues under well-controlled conditions.
SUBJECTS AND METHODS

Chemicals
PLP, 4-pyridoxic acid (4-PA), pyridoxal hydrochloride, pyridoxamine-5#-phosphate (PMP) and all other chemicals were purchased from Sigma. HPLC-grade methanol was purchased from Echo. Celecoxib and naproxen were obtained as commercial drugs [Celebrex (Pfizer) and Genuproxin (Genuine)].
Human-study protocol
The study protocol was approved by the institutional clinical research ethics committee. A total of 150 adults (aged $18 y) with rheumatoid arthritis who met the American College of Rheumatology criteria for rheumatoid arthritis (25) were recruited prospectively from 2008 to 2010 at the Allergy, Immunology and Rheumatology outpatient clinic, Department of Immunology and Rheumatology, Taichung Veterans General Hospital. Written informed consent was obtained from all subjects before enrollment in accordance with the regulation of the Institution. Subjects with pregnancy, anemia (hemoglobin concentration #10 mg/dL), thrombocytopenia (platelet count ,50,000 cells/mL), abnormal serum hepatic transaminase (aspartate aminotransferase or alanine aminotransferase concentration .50 IU/L), diabetes, or cancer were excluded. Subjects were asked to avoid taking over-the-counter aspirin and vitamin supplements $1 mo before enrollment in the study. Blood chemistry analyses were performed at the general clinical research laboratory at Taichung Veterans General Hospital that included, creatinine, C-reactive protein, white blood cell count, platelets, and hemoglobin.
Duration of cyclooxygenase inhibitor use
NSAIDs used in study subjects included celecoxib, meloxicam, nimed, sulindac, and diclofenac. In subjects who were taking cyclooxygenase inhibitors, w74% of them had been taking NSAIDs .6 mo (mean duration: 16 mo). The duration of NSAID use was based on the prescription history that was confirmed by a questionnaire administered by the study personnel. The Duration of NSAID use was divided into the following 3 categories: no use, #6 mo, or .6 mo.
Human-study experimental protocol
Subjects were asked to fast overnight for 12 h for the study blood draw. The following morning, fasting blood samples from subjects were collected into tubes containing EDTA and chilled immediately on ice for the determination of the vitamin B-6 profile and homocysteine. Each patient was instructed to complete the Stanford Health Assessment Questionnaire to evaluate how well the patient was able to perform routine activities (26) ; a total of 20 categories of questions were used to evaluate how well the patient was able to manage routine activity. Assessments of disease activity were rated on a scale from 0 to 3, where 0 = remission, 1 = mild; 2 = moderate, and 3 = severe. A visual analog scale was used for the assessment of the pain score; and a tender joint count (28-joint count) (14, 26) was performed for each subject by study physicians . Gene expression of vitamin B-6 metabolic enzymes in human peripheral blood mononuclear cells Plasma and RNA samples were isolated and stored at 2808C until analysis. Peripheral blood mononuclear cells were collected from heparinized blood and isolated by using Ficoll-Hypaque centrifugation (Sigma), and RNA was isolated by using TRIzol reagent (Invitrogen). The quality of all RNA samples was checked on agarose gel. Complementary DNA was copied from 2 mg total RNA by using Moloney murine leukemia virus reverse transcriptase (Promega) primed with oligo(dT) (27) . Equal amounts of complementary DNA were taken from each reverse-transcription reaction mixture for real-time polymerase chain reaction (PCR) amplification by using specific primers for pyridoxal kinase (PDXK), PLP phosphatase (PDXP), PMP oxidase [PM(N)PO] and for 18S as internal controls. Real-time PCR analysis was performed by using a SYBR Green PCR Reagents Kit (Applied Biosystems).
Dietary intake of study subjects
Subjects were instructed to complete a food diary at enrollment. Each subject was interviewed by a registered dietitian for validation of the food diary on the day of blood collection. A colored book with 1:1-size food photos were used to standardize portion size in subjects. Nutrient composition was calculated with the use of Nutritionist Professional software Dietician version 1 (27) (E-kitchen Business Corporation) in combination with the Taiwan food-composition database established by the Department of Health in Taiwan.
Animals, diet, and study conditions
Both animal studies were approved by the Institutional Animal Care and Use Committee. Study 1 investigated the impacts of physiologic doses of selective cyclooxygenase-2 inhibitor celecoxib and nonselective cyclooxygenase inhibitor naproxen on tissue vitamin B-6 status. Study 2 investigated the effects of longterm physiologic doses of celecoxib and naproxen treatments on vitamin B-6 metabolism in hypercholesterolemic animals. In study 1, 18 male, 4-wk-old C57BL/6J mice (National Laboratory Animal Center) were fed a standard AIN-93M diet (Dyets) that contained 6 mg pyridoxine/kg diet throughout the study period (28) . In study 2, 18 male, 7-wk-old Syrian hamsters (National Laboratory Animal Centern) were fed a modified AIN-93M hypercholesterolemic diet (10% corn oil plus 0.2% cholesterol) that contained 6 mg pyridoxine/kg diet throughout the study period (Dyets). After 2 wk of adaptation, animals in both studies were divided by weight into vehicle control, naproxen, and celecoxib groups. All animals were maintained in a temperature-and humidity-controlled environment (20-258C) with a 12-h light/12-h dark cycle with food and sterilized water ad libitum. Food intakes were measured daily, and body weight was recorded 2 times/wk. A 24-h urine specimen was collected from each animal; the excretion of urinary 4-pyridoxic acid and creatinine was subsequently measured by using an enzymatic colorimetric assay according to the manufacturer's instructions (Randox Laboratories Ltd).
Clinical relevance of celecoxib and naproxen regimens
On the basis of the life expectancy of animal models, the duration of study 1 would have reflected 4-5 y; study 2 would have reflected .10 y of long-term clinical use of these treatments in humans. According to the Guideline for the Timing of Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (29), a study treatment that continued for .10% of the test subject's life span would be considered "chronic." The conversion of animal doses to human equivalent doses was calculated on the basis of the body surface area (30) . On the day of the treatment, animals in treatment groups received celecoxib or naproxen treatments (freshly dissolved in saline) by gastric feeding at the beginning of the dark cycle at 1800. Control animals received the same volume of 0.9% saline as the treatment by gastric feeding. In study 1, mice received naproxen (5 mg $ kg body weight 21 . Celecoxib is generally administered to arthritis patients at a dosage of 200 mg/d; naproxen is generally used at a dosage of 100-200 mg/d. The mean daily dose of celecoxib in our study subjects was 262 mg (range: 100-400 mg). Doses used in our studies were well below doses used in patients who suffer from chronic arthritis.
Blood and tissue sample collection and preparation
After study periods, fasting blood samples were drawn from the orbital venous sinus vein into heparin-coated tubes. Plasma was separated immediately by centrifugation and stored at 2808C. Animals were killed by exsanguination under deep anesthesia. The liver and kidneys were immediately excised and stored in 2808C until analysis.
Determination of vitamin B-6 and homocysteine concentrations
Plasma was precipitated with 0.4 M ice-cold perchloric acid for deproteinization before HPLC analysis. Animal tissue was homogenized in 10 vol 0.4 M ice-cold perchloric acid. Extracts were kept on ice for 30 min, centrifuged at 14,000 3 g for 10 min at 48C, and the supernatant fluid was frozen at 2808C (31). The precolumn semicarbazide dramatization followed the procedure previously described (32) with modifications for the additional detection of vitamin B-6 vitamers in tissues. Briefly, perchloric acid-extracted tissue supernatant fluid was incubated (30 min in the dark) with derivatization solution (250 mg semicarbazide and glycine/mL). Samples were filtered through 0.45-mm microspin filters before HPLC analysis (28) . The HPLC system consisted of a Hitachi L-2130 intelligent pump connected to an L-2480 fluorescence detector and L-2100 autosampler (Hitachi). Separation was achieved by using a Mightysil RP-18 column (250 3 4.6-mm inside diameter; particle size: 5mm) (Kanto Corp). Mobile phase A consisted of 60 mmol disodium hydrogen phosphate/L that contained 9.5% methanol (vol:vol) and 400 mg EDTA disodium salt/L and adjusted to pH 6.5 with phosphoric acid. Mobile phase B consisted of 60 mmol disodium hydrogen phosphate/L and 400 mg EDTA disodium salt/L adjusted to pH 6.0 with phosphoric acid. To detect vitamin B-6 vitamer PMP, the fluorescence detector was programmed with excitation and emission wavelengths at 325 and 400 nm to detect PMP. The intra-assay and interassay CVs were both ,10%, and the recovery was between 90% and 110%. The detailed HPLC procedure was described elsewhere (E-PI Chiang, SJ Lin, H-Y Chang, HC Hou, unpublished data, 2011). Plasma total (unbound and bound) homocysteine, which was measured by using HPLC with fluorometric detection, was determined by using the method described previously (33) .
Statistical analysis
Nonnormally distributed variables were log transformed to reach normality for statistical analyses. One-factor ANOVA was used for multiple comparisons; and Bonferroni corrected P values were calculated in post hoc analyses. Pearson's correlation coefficients were calculated between continuous variables including concentrations of vitamin B-6 vitamers, gene-expression amounts of PDXK, PDXP, and PM(N)PO, and the duration of NSAIDs (in mo). Differences were considered significant at P , 0.05. All statistical analyses were performed with Systat 11.0 for Windows software (Systat Software Inc).
RESULTS
Clinical characteristics
The Health Assessment Questionnaire disability score of study subjects indicated remission to mild disease activity in study subjects. The mean (6SD) Health Assessment Questionnaire disability score of patients (n = 147) was 0.43 6 0.68 (on a 0-3 scale), which indicated that the conditions were well controlled ( Table 1) . The mean disease duration was 13.0 y (median duration: 12.5 y). Of 150 patients originally enrolled in the study, 3 subjects dropped out (or were excluded) because they continued vitamin supplementation, or there were concerns over discontinuing their vitamin supplements. All patients were taking medications for symptom relief and had been taking the same medications for $2 mo. Of 147 patients who completed the study, 26 subjects (18%) were not taking any kind of cyclooxygenase inhibitors; 121 subjects (82%) were taking cyclooxygenase inhibitors (users taking each medication: celecoxib, 1 One-factor ANOVA was used for multiple comparisons. There were no significant differences between groups. CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; RA+COX .6 mo, subjects with rheumatoid arthritis who used cyclooxygenase inhibitor .6 mo; RA+COX #6 mo, subjects with rheumatoid arthritis who used cyclooxygenase inhibitor #6 mo; RA-COX, no use, subjects with rheumatoid arthritis who were non-cyclooxygenase inhibitor users.
2 Median; 95% CI in parentheses (all such values).
3 HAQ contained 20 categories of questions that evaluated how well the patient was able to manage routine activity. Assessments of disease activity were rated on a scale of 0-3, where 0 = remission, 1 = mild, 2 = moderate, and 3 = severe. A visual analog scale was used for the assessment of the pain score; and a tender joint count (28-joint count) was performed by study physicians. n = 63; meloxicam, n = 35; sulindac, n = 12; nimed, n = 8; and diclofenac, n = 3). Of 121 cyclooxygenase inhibitor users, 89 subjects (74%) had used NSAIDs .6 mo. Subjects were divided into 3 groups according to durations of cyclooxygenase inhibitor use as follows: nonusers (n = 26) who did not use any NSAIDs during and $2 mo before enrollment, subjects who used cyclooxygenase inhibitor #6 mo (n = 32), and subjects who used cyclooxygenase inhibitor .6 mo (n = 89). Clinical and demographic characteristics of subjects are shown in Table 1 . Distributions of sex, age, BMI (in kg/m 2 ), disease duration, disease activity, and blood chemistry measurements were similar in the 3 groups. The percentage of disease-modifying antirheumatic drug use, treatment duration, or weekly dose did not significantly differ in the 3 groups, which suggested that the potential impacts on biochemical variables from other drugs were minimal.
Lower vitamin B-6 concentrations were present in patients taking cyclooxygenase inhibitors Dietary intakes of calories, protein, and vitamin B-6 or the ratio of vitamin B-6 to protein ratio did not differ in noncyclooxygenase users and cyclooxygenase users ( Table 2) . Compared with the general population in the Nutrition and Health Survey in Taiwan (NAHSIT), our subjects had a lower mean energy consumption [current study (women: 1212 kcal; men: 1429 kcal) compared with the NAHSIT (women: 1459 kcal; men: 1821 kcal)]. These findings were consistent with a lower prevalence in overweight/obesity (BMI $ 24) in our subjects (,32%) compared with that (.51%) in the 2005-2008 NAH-SIT (34). Our subjects had a similar percentage of energy from fat (30.2%) compared with that in the NAHSIT (31.4%), more energy from carbohydrate (56.3% in the current study compared with 51.7% in the NAHSIT), but lower energy from protein (13.5% in the current study compared with 17% in the NAHSIT). The mean vitamin B-6 intake in our subjects was slightly lower than that in the NAHSIT, which was consistent with the fact that subjects consumed less protein-containing foods that were also common sources for vitamin B-6. The lower vitamin B-6 intake in study subjects could have also been associated with the exclusion of supplement users. The mean intake ratio of vitamin B-6 to protein in our subjects (0.02 6 0.01; n = 147) was similar to that of subjects in the NAHSIT (0.02 6 0.02; n = 1911) (34) .
Plasma PLP and pyridoxal concentrations of study subjects were in good agreement with rheumatoid arthritis patients in previous studies (14, 16, 35, 36) . Compared with non-cyclooxygenase users, plasma PLP concentrations tended to be lower in shortterm users (# 6 mo; P , 0.1) and were significantly lower in long-term users (.6 mo; P = 0.003). The ratio of plasma PLP to pyridoxal, which may reflect the efficiency to convert vitamin B-6 into its active form, was significantly reduced in all cyclooxygenase users (Table 2) .
On the other hand, plasma homocysteine concentrations or gene expressions of PDXK, PDXP, and PM(N)PO, which ware major metabolic enzymes of vitamin B-6 (Figure 1 ), did not differ between groups (Table 2) .
Specific cyclooxygenase-2 inhibitor and nonselective NSAID alter vitamin B-6 metabolism in vivo
In both mouse and hamster models, the mean body weight and food intake did not differ in animals that received saline, celecoxib, or naproxen as the treatment. Plasma creatinine concentrations remained unaffected in these animals throughout the study (data not shown). These results suggested that treatments of celecoxib or naproxen at these physiologic doses did not affect animal growth, food consumption, or renal function throughout the study period. 1 All values are medians; 95% CIs in parentheses. One-factor ANOVA was used for multiple comparisons, and Bonferroni-corrected P values were calculated in post hoc analyses. Values in the same measure with different superscript letters are significantly different. *P , 0.05, **P , 0.01. PDXK, pyridoxine kinase; PDXP, pyridoxal-5#-phosphate phosphatase; PLP, pyridoxal-5#-phosphate; PM(N)PO, pyridoxamine (pyridoxine)-5#-phosphate oxidase; RA+COX .6 mo, subjects with rheumatoid arthritis who used cyclooxygenase inhibitor .6 mo; RA+COX #6 mo, subjects with rheumatoid arthritis who used cyclooxygenase inhibitor #6 mo; RA-COX, no use, subjects with rheumatoid arthritis who were non-cyclooxygenase inhibitor users.
2 Relative messenger RNA expressions of major vitamin B-6 metabolic enzymes in peripheral blood mononuclear cells.
Although plasma PLP or pyridoxal concentrations did not change by the 7-or 22-wk point of cyclooxygenase inhibitor treatments in these models (Tables 3 and 4) , celecoxib and naproxen significantly changed the vitamin B-6 status in tissues. In mice fed the AIN93M diet, the 7-wk celecoxib treatment resulted in a 12% reduction in PLP in the liver; and the 7-wk naproxen treatment decreased hepatic PMP and PLP concentrations (Table 3) by 12% and 21%, respectively. In hypercholesterolemic hamsters, the 22-wk long-term celecoxib and naproxen treatments decreased hepatic PLP concentrations by 30% and 28%, respectively ( Table 5 ). In the kidney, naproxen, but not celecoxib, decreased PLP in both models. In hamsters that received 22 wk NSAID treatments, celecoxib and naproxen drastically decreased pyridoxal by 60% and 70%, respectively (Table 5 ). Because none of these treatments affected dietary intakes in the models, reductions in tissue vitamin B-6 vitamers observed in these animals were likely caused by the interference of vitamin B-6 metabolism and not by reduced vitamin B-6 consumption. The 22-wk long-term celecoxib and naproxen treatments tended to decrease the ratio of PLP to pyridoxal in the liver, and these treatments significantly decreased the ratio of pyridoxal to pyridoxic acid in the kidney (Table 5 ).
DISCUSSION
Our current study underscores the need for continued surveillance and pharmacologic research of cyclooxygenase inhibitors in clinical practice by having shown, to our knowledge, novel findings pertaining to the interfering effects of specific NSAID treatments on vitamin B-6 metabolism.
Abnormal vitamin B-6 status in rheumatoid arthritis has been recognized for decades, but the basis of the low plasma PLP concentrations in human inflammation remains to be established. In this study, we provided an additional cause that may in part account for the poor vitamin B-6 status present in subjects who suffer from chronic inflammation. We showed significant findings on interfering effects of specific long-term NSAID treatments on vitamin B-6 metabolism. None of the treatments affected dietary intake in the models, which suggested that reductions in vitamin B-6 vitamers observed in these animals were unlikely due to reduced vitamin B-6 consumption but rather to the interference in the uptake, retention, or use of vitamin B-6. The effects of celecoxib and naproxen on vitamin B-6 status are summarized in Table 5 .
The cause of vitamin B-6 depletion by NSAID treatment is unknown. Studies have shown constitutive cyclooxygenase expression in the kidney and the significance of cyclooxygenase-2 in regulating renal function (37) (38) (39) . Hypertensive effects of celecoxib may have been associated with effects of this drug on the kidney because cyclooxygenase-2 plays a role in regulating renin release, and the selective inhibition of cyclooxygenase-2 in the rat results in a reduction in plasma renin activity (40) . Doses of celecoxib in the range used for the treatment of rheumatoid arthritis significantly suppressed the urinary excretion of prostacyclin metabolites in healthy volunteers (41) . Many patients with chronic renal failure often develop vitamin B-6 deficiency (42) and have a higher vitamin B-6 demand (43). Low plasma PLP concentrations have been shown in renal disorders (44) . However, uremia is unlikely to be the main cause of poor vitamin B-6 status 1 All values are means 6 SDs. One-factor ANOVA was used for multiple comparisons, and Bonferroni-corrected P values were calculated in post hoc analyses. Values in the same measure with different superscript letters are significantly different. Compared with controls: *P , 0.05, **P , 0.01, ***P , 0.001. NSAID, nonsteroidal antiinflammatory drug; PLP, pyridoxal-5#-phosphate; PMP, pyridoxamine 5#-phosphate; 4-PA, 4-pyridoxic acid.
in these subjects because neither human subjects nor animals had abnormal creatinine. Furthermore, the effect of NSAIDs on kidney function appears to be acute and to recede over time (45) ; however, most of our study subjects had used NSAIDs .1 mo.
The lower ratio of PLP to pyridoxal in human plasma as well as in the liver of animals receiving long-term celecoxib and naproxen indicated that these drugs may have specifically interfered with the conversion of vitamin B-6 into its coenzyme form in the major organ of metabolism. Celecoxib and naproxen both resulted in significant reductions of pyridoxal in the kidney of hamsters that received NSAID treatments .20 wk. In vitamin B-6 metabolism, the delivery, transport, and uptake of vitamin B-6 is mainly in the form of pyridoxal in the body (46) . Renal tubules play a critical role in salvaging vitamin B-6 from luminal filtrate (47) (48) (49) . Experiments showed that the uptake of radioisotope vitamin B-6 by freshly isolated rat renal proximal tubular cells was temperature dependent and exhibited saturation kinetics (47) . In vitamin B-6 catabolism, pyridoxal arising from the dephosphorylation of PLP can be irreversibly converted to 4-PA by either an NAD-dependent dehydrogenase or a FAD-dependent aldehyde oxidase (46) (Figure 1 ). Mean 4-PA excretions appeared to be slightly elevated in animals that received long-term cyclooxygenase inhibitors, but the alterations did not reach significance. Because altered pyridoxal concentrations were observed in the kidney but not in the liver or the circulation, significant reductions of pyridoxal in the kidney may have reflected the poor reabsorption of vitamin B-6 although more studies are needed for this postulation. How NSAIDs specifically interfere with the interconversion of vitamin B-6 vitamers are currently under investigation.
In patients with rheumatoid arthritis, the plasma PLP concentration is a good diagnostic indicator of functional vitamin B-6 status because it was inversely correlated with the homocysteine increase in response to a methionine load and inversely correlated with the xanthurenic acid excretion in response to a tryptophan load (36) . A functional assessment of vitamin B-6 status would help to determine the biological relevance of the low circulating vitamin B-6 concentration in cyclooxygenase-treated humans and animals. The vitamin B-6 functional status is under investigation in animal models.
It was reported that mice or hamsters, rather than guinea pigs or rats, would be better species for quantitative studies of pyridoxine-glucoside bioavailability and associated enzymatic processes (50) . However, these 2 animal models may not be the best system for studying the drug effects of vitamin B-6 metabolism. It remains to be investigated whether these animals are ideal models of what occurs in humans because the cyclooxygenase inhibitors affected plasma PLP in humans but not in animal models.
Although the results from our human subjects were derived from an observational design, the interference of NSAIDs on vitamin B-6 metabolism was reinforced by the consistency of our results in 2 in vivo models. With the careful control of known factors that might have affected outcomes (dietary vitamin B-6 contents, age, sex, and type and doses of NSAIDs), these models provided a cause-effect relation between physiologic NSAID use and tissue-specific vitamin B-6 depletion. In hamsters that 2 A trend of a difference compared with controls, P , 0.1.
received NSAID treatments, celecoxib and naproxen drastically decreased pyridoxal by 60-70%, which indicated that the longterm use of cyclooxygenase inhibitors, regardless if selective or nonselective cyclooxygenase-2 inhibitors, could disrupt vitamin B-6 metabolism in the kidney. Because the case number of each individual conventional NSAIDs was low, the comparison of each drug on vitamin B-6 metabolism was not feasible in the human subjects. More studies of NSAIDs on vitamin B-6 absorption are needed in this regard. Furthermore, NSAIDs are used primarily by humans who suffer from chronic inflammation. This is the same population likely to be deficient in vitamin B-6. One would expect that the control of their inflammatory conditions would help improve their vitamin B-6 status. However, results of the current study suggested that the use of NSAIDs in the dose range used for the treatment of rheumatoid arthritis may deplete vitamin B-6 in important tissues of vitamin B-6 metabolism. Effects of conventional NSAIDs and selective cyclooxygenase-2 inhibitors on renal function could result in detrimental effects on vitamin B-6 status. Because of the very high coincidence of coronary disease, vitamin B-6 deficiency, and inflammation, this population may represent the largest portion of the population for whom NSAIDs and selective cyclooxygenase inhibitors are prescribed, and the extensive use of these drugs puts many of them at risk. The selection of antiinflammatory treatment is of particular significance for this population. However, relatively fewer studies have investigated the link between medication use and impaired vitamin B-6 status in chronic inflammation. With the use of 2 independent in vivo models, we recently showed a potential advantage of clinical prednisolone use in the treatment of inflammation with respect to vitamin B-6 status (28).
In conclusion, to our knowledge, the current study presents new findings that long-term use of cyclooxygenase inhibitor physiologic doses may impede the synthesis of the coenzymatically active form of vitamin B-6. With consideration that that the cause of vitamin B-6 depletion in inflammation remains unknown, this study provides an additional cause that could account for the low circulating vitamin B-6 concentration in human inflammation but also raises concerns about the long-term clinical use of NSAIDs. In light of reports of cardiovascular harm associated with cyclooxygenase inhibitors, our data provide evidence that the use of certain cyclooxygenase inhibitors may increase risk of cardiovascular diseases via impaired vitamin B-6 status. Whether these alterations were due to the direct inhibition of the conversion into its coenzyme form, poor reabsorption, or acceleration of excretion remain to be further investigated. Nonetheless, vitamin B-6 status should be more-carefully monitored in long-term NSAID users. Future randomized placebo-controlled studies are needed to determine the impacts of antiinflammatory cyclooxygenase inhibitor use on vitamin B-6 metabolism in humans.
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